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Abstract
Background & Aims: Chronic hepatitis B virus (HBV) infection accounts for 30%-50% 
of cirrhosis related deaths in sub-Saharan Africa (SSA). Since HBV-related cirrhosis is 
an indication for immediate antiviral therapy and cancer surveillance, we aimed to 
estimate the prevalence of cirrhosis among treatment-naïve patients with chronic 
HBV infection in SSA.
Methods: We performed a systematic review of published articles which evaluated 
liver fibrosis stage among treatment-naïve HBV-infected individuals who presented to 
care in SSA. Our primary outcome was the prevalence of cirrhosis in HBsAg-positive 
persons, which was estimated using random-effects meta-analysis. Risk factors for 
cirrhosis were explored using subgroup-analyses and multivariable meta-regression.
Results: Of 2129 articles identified, 17 met our eligibility criteria. The studies de-
scribed 22 cohorts from 13 countries, including 13 cohorts (3204 patients) with 
chronic HBV mono-infection and nine cohorts (688 patients) with HIV/HBV-
coinfection. Liver fibrosis was assessed using transient elastography (10 cohorts), 
APRI score (11 cohorts), and Fibrotest (one cohort). The pooled prevalence of cir-
rhosis was 4.1% (95% confidence interval [CI] 2.6-6.4) among studies from primary 
care facilities or general population, compared to 12.7% (95% CI 8.6-18.3) in studies 
performed in referral or tertiary care facilities (adjusted odds ratio 0.29, 95% CI 0.15-
0.56). We found no association between cirrhosis and age, gender, fibrosis test used 
or HIV-coinfection.
Conclusions: Depending on the setting, between 4% and 13% of HBV-infected in-
dividuals in SSA have cirrhosis and need immediate antiviral therapy. These esti-
mates should be considered when planning HBV treatment strategies and resource 
allocation.
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1  | INTRODUC TION
Chronic hepatitis B virus (HBV) infection is the leading cause of liver-
related deaths worldwide and accounts for around one third of all 
deaths attributed to cirrhosis. In sub-Saharan Africa (SSA), where 
most infections occur at birth or during early childhood, 30%-50% 
of all cirrhosis-related deaths can be attributed to chronic HBV in-
fection.1 Antiviral treatment of patients with chronic HBV infection 
prevents the progression of cirrhosis2 and reduces the incidence of 
hepatocellular carcinoma (HCC) in patients with and without HIV in-
fection,3,4 thereby decreasing HBV-related morbidity and mortality. 
Although treatment eligibility criteria for individuals without cirrho-
sis vary across guidelines and their interpretation is often subject 
to debate, the presence of cirrhosis is a clear indication for antivi-
ral therapy and ultrasound-based HCC screening.5,6 Large studies 
of HBV-monoinfected4,7 and HIV/HBV-coinfected individuals3 have 
confirmed the increased risk of developing HCC among individuals 
with cirrhosis.
However, few large-scale studies have evaluated the prevalence 
of HBV-related liver fibrosis and cirrhosis in SSA, where the pres-
ence of additional environmental and infectious risk factors may 
further accelerate the progression of liver disease. Thus, knowing 
the prevalence of HBV-related cirrhosis is crucial for evaluating anti-
viral therapy needs for SSA. In 2016, the World Health Organization 
(WHO) started to advocate for the elimination of viral hepatitis as a 
public health problem. Specific objectives include the diagnosis of 
90% of all individuals with chronic HBV infection, and the treatment 
of 80% of eligible individuals by 2030.8 In order to inform global 
resource allocation strategies, we performed a systematic review 
and meta-analysis to assess the prevalence of cirrhosis among treat-
ment-naïve HBV-infected individuals in SSA.
2  | METHODS
2.1 | Search strategy and selection criteria
We performed a systematic search of PubMed, EMBASE, African 
Index Medicus (via Global Index Medicus), Cochrane Central 
Register of Controlled Trials (CENTRAL), Web of Science and 
CINAHL to identify articles, which reported the proportion of 
treatment-naïve HBsAg-positive individuals who presented with 
cirrhosis (see appendix for the detailed search strategy). We con-
sidered published papers from inception until June 25, 2020 with 
original data in which liver fibrosis was assessed systematically in 
cohorts from sub-Saharan Africa. We considered all types of liver 
fibrosis assessments, including liver biopsy, transient elastography 
and serological scores such as the AST-to-platelet ratio index (APRI), 
fibrosis-4 (FIB-4) and Fibrotest. Studies which selected participants 
based on symptoms or stage of liver disease, and studies which as-
sessed less than 20 HBV-infected individuals were excluded. We did 
not apply any restrictions on time frame, age of study participants or 
language of publication. Title, abstract and full text screening as well 
as data extraction were performed independently by four investiga-
tors (DW, BS, CB and GW) and discrepancies were discussed until 
a consensus was reached. Risk of bias was assessed using a criti-
cal appraisal tool for prevalence studies.9 The reporting of the study 
follows the Preferred Reporting Items for Systematic Review and 
Meta-Analyses (PRISMA) guidelines. The protocol for this system-
atic review and meta-analysis was registered with the International 
Prospective Register of Systematic Reviews (PROSPERO, registra-
tion number CRD42020180422).
2.2 | Outcomes and definitions
The primary outcome was the proportion of treatment-naïve HBV-
infected individuals with cirrhosis, whereas the prevalence of signifi-
cant liver fibrosis was assessed as a secondary outcome. We used 
the transient elastography (TE) cut-offs reported by the authors 
which varied between studies. One study10 used a transient elastog-
raphy cut-off of >9.3 kPa to define significant fibrosis; as this value 
is above the WHO-recommended threshold for significant fibrosis 
in HBV infection (>7.5-8.5 kPa),5 we re-categorized individuals with 
a value >9.3 kPa into the cirrhosis group. In another study, a sub-
stantially lower than the WHO-recommended threshold was used 
K E Y W O R D S
antiviral treatment, cirrhosis, Hepatitis B virus, liver fibrosis, Sub-Saharan Africa, systematic 
review
Key points
• Liver cirrhosis is the most important driver of hepatitis B 
virus (HBV)-related morbidity and mortality.
• Individuals with liver cirrhosis should receive immedi-
ate antiviral treatment with tenofovir and screening for 
hepatocellular carcinoma (HCC).
• In this meta-analysis of 17 studies evaluating liver fibro-
sis stage among treatment-naïve HBV-infected individu-
als in sub-Saharan Africa (SSA), the pooled prevalence 
of liver cirrhosis was 6.7% and differed significantly be-
tween primary care facilities (4.1%) and tertiary care or 
referral hospitals (12.7%).
• Based on our findings, an estimated 2.5 of 60 million in-
dividuals with chronic HBV infection in SSA have liver 
cirrhosis and need antiviral therapy and surveillance for 
liver cancer.
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to define significant fibrosis (≥5.9 kPa)11; since the authors provided 
estimates based on transient elastography values ≥7.6 kPa, we used 
these numbers to define significant fibrosis. APRI scores above 1.5 
were categorized as significant fibrosis, and above 2.0 as cirrhosis.5 
Studies, which reported data from more than one country or more 
than one patient population were separated into cohorts. If more 
than one method of fibrosis assessment was available, we prior-
itized transient elastography, followed by APRI and FIB-4. For each 
cohort, only one method of assessment was used to calculate the 
prevalence, and only the first fibrosis assessment (prior to any anti-
viral treatment) was considered when repeated measurements were 
available.
2.3 | Data analysis
The prevalence of cirrhosis and significant fibrosis was estimated 
using random intercept logistic regression and logit transformed 
proportions. The 95% confidence intervals (CI) were derived using 
the exact method, and statistical heterogeneity was assessed using 
the Cochrane's Q and the I2 statistic. To explore potential causes of 
heterogeneity, we performed subgroup analyses according to the 
test used (transient elastography, APRI, FIB-4 and Fibrotest®), co-
hort category (referral/teaching hospital and primary care/general 
population), and whether HIV co-infection was present or not. In 
addition, we performed sensitivity analyses including only studies 
which used TE, the test with highest sensitivity and specificity for 
detecting liver fibrosis and cirrhosis.5 A sensitivity analysis restricted 
to studies performed in HBV-monoinfected populations was per-
formed to assess the impact of cohort categories in this subpopula-
tion. Risk factors for cirrhosis were modelled using univariable and 
multivariable meta-regression. All analyses were performed using 
the meta12 package for R version 4.0.
3  | RESULTS
3.1 | Description of the study population
Of 2129 potential articles obtained through our systematic search, 
17 met our eligibility criteria (Figure S1). The studies described 22 
different cohorts including 3892 patients with chronic HBV infec-
tion from 13 different countries in sub-Saharan Africa: Ethiopia (1), 
the Gambia (3), Ghana (1), Ivory Coast (1), Mali (1), Mozambique 
F I G U R E  1   Overview of cohorts contributing data to the meta-analysis. Countries with available data (A) and distribution of cohorts with 
data from primary care/general population cohorts or referral/teaching hospitals (B)
(A) (B)
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(1), Nigeria (3), Senegal (1), South Africa (1), Tanzania (4), Togo (1), 
Uganda (1) and Zambia (2, Figure 1). Fourteen cohorts included 
patients from the general population (eg primary care or screen-
ing of blood donors, 2021 patients [51.9%]), and eight studies re-
cruited patients from referral centers or teaching hospitals (1871 
patients [48.1%]). The largest contributions to the study populations 
stemmed from three cohorts from the Gambia (general population 
screening, n = 1107, 28.4%) and one cohort from Ethiopia (referral 
centre, n = 1190, 30.6%). Thirteen cohorts included HBV mono-in-
fected individuals (3204 patients, 82.3%), and nine cohorts included 
HIV/HBV coinfected individuals (688, 17.7%). The median age of the 
study population ranged from 27 to 38 years, and the proportion of 
females ranged from 0% to 65% (Table 1). Seven studies included 
information about the prevalence of HBeAg positivity, which ranged 
from 3% to 28%.
The assessment of liver fibrosis or cirrhosis relied mostly on TE 
(10 cohorts), followed by APRI and FIB-4 (11 cohorts), and Fibrotest® 
(one cohort). No study reported results from liver biopsy. Studies 
used TE cut-off values ranging from 9.4 to 12.3 kPa for defining cir-
rhosis and from 5.9 to 9.3 kPa for significant fibrosis. Estimates for 
liver fibrosis were reported in all but three cohorts, and cirrhosis was 
reported in 16 cohorts.
3.2 | Prevalence of liver cirrhosis
The pooled prevalence of cirrhosis was 6.4% (95% confidence 
interval [CI] 4.1-9.9, I2 = 87%) overall, with estimates from in-
dividual studies varying between 0% in a small cohort of HBV-
monoinfected individuals in Ivory Coast16 and 22.6% among HIV/
HBV-coinfected individuals in Nigeria.10 The most important fac-
tor contributing to heterogeneity of cirrhosis prevalence was the 
setting in which the study was performed: Whereas the prevalence 
was 12.7% (95% CI 8.6-18.3, I2 = 73%) in studies performed at re-
ferral or teaching hospitals, the estimate from studies performed 
in primary care facilities or as part of general population screening 
was 4.1% (95% CI 2.6-6.4, I2 = 52%, P-value for between-group 
difference <0.001, Figure 2). The pooled prevalence of cirrhosis 
was higher among HIV/HBV co-infected individuals (11.3%, 95% 
CI 6.3-19.5, I2 = 69%) than in individuals without HIV infection 
(4.6%, 95% CI 2.4-8.6, I2 = 90%, P-value for between-group differ-
ence 0.04, Figure 3A). Studies based on transient elastography re-
ported a cirrhosis prevalence of 6.1% (95% CI 3.3-11.2, I2 = 89%), 
compared to 7.1% in studies based on APRI, (95% CI 4.3%-11.5, 
I2 = 45%), and 5.4% (95% CI 2.7%-10.5%) in the one which used 
Fibrotest (P for between-group difference 0.81, Figure 3B). Neither 
percentage of women within the studies (P = .90), median age of 
the study population (P = .78), fibrosis test used (P = .87), nor HIV 
coinfection status (P = .10) were significantly associated with the 
prevalence of cirrhosis in univariable meta-regression (Table S1). 
In multivariable meta-regression adjusted for co-infection status 
and test used, study setting was the only factor which remained 
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cohorts from primary care or general population screening vs re-
ferral or teaching hospitals, 95% CI 0.15-0.56).
A sensitivity analysis including only studies which used tran-
sient elastography to evaluate cirrhosis revealed similar results: The 
overall pooled prevalence of cirrhosis was 6.1% (95% CI 3.3-11.2, 
I2 = 89%), whereas the estimate was 15.9% (95% CI 10.0-24.4, 
I2 = 73%) in studies at referral or teaching hospitals, and 3.8% (95% 
CI 2.0-7.3, I2 = 65%) among studies performed in primary care or 
as general population screening (residual heterogeneity I2 = 67%, 
Figure S2). After restricting the main analysis to studies performed 
in HBV-monoinfected individuals, studies at referral or teaching 
hospitals remained associated with a higher prevalence of cirrhosis 
(10.3%, 95% CI 4.8-20.7, I2 = 81%) compared to studies from primary 
care or general population cohorts (3.6%, 95% CI 2.1-6.1, I2 = 59%, 
Figure S3). To further examine the robustness of our results, we ex-
cluded the largest study from Aberra et al (n = 1190) in an additional 
analysis, and found similar estimates (Figure S4).
3.3 | Prevalence of significant liver fibrosis
The proportion of individuals with significant fibrosis ranged from 
4.0% to 35.4% across cohorts, with an overall pooled prevalence 
of 12.0% (95% CI 8.8-16.4, I2 = 88%). There was no significant dif-
ference between cohorts from primary care or general populations 
(10.4%, 95% CI 6.4-16.8, I2 = 90%) and those from referral or teach-
ing hospitals (16.4%, 95% CI 11.9-22.3, I2 = 64%), and between-
study heterogeneity was high (Figure S5). The pooled prevalence 
was similar among studies which used transient elastography (11.6%, 
95% CI 7.4-17.8, I2 = 91%) and those which used APRI (11.2%, 95% 
CI 7.2%-17.0%, I2 = 64%), whereas the prevalence was lower in the 
cohort which relied on FIB-4 (4.3%, 95% CI 1.1%-15.5%), and higher 
in the cohort which used Fibrotest® (35.4%, 95% CI 28.1%-43.4%).
3.4 | Assessment of study quality
Most studies were performed among a sample of individuals rep-
resentative of the target population of the specific study, and all 
studies measured the outcome in a standardized and reliable way 
within their study population. Whereas most studies reported a sys-
tematic screening of HIV among all participants, one study did not 
state whether HIV was screened for.20 However, some studies failed 
to describe how patients were selected into the studies, and only a 
minority of studies performed random sampling of eligible patients. 
In addition, the sample size was small in most studies, and the main 
outcome was incompletely assessed in three studies. Whereas 50% 
of all studies relied on transient elastography to assess liver fibrosis, 
the less sensitive APRI method was mainly used in studies of HIV/
HBV co-infected patients (Table S2).
F I G U R E  2   Proportion of individuals with liver cirrhosis, stratified by cohort category
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F I G U R E  3   Proportion of individuals with liver cirrhosis, stratified by HIV infection status (A) and by fibrosis test used(B).
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4  | DISCUSSION
Among treatment-naïve HBV-infected individuals in sub-Saharan 
Africa, the prevalence of cirrhosis was 4.1% (95% CI 2.6-6.4) in stud-
ies performed at primary care facilities or as part of general popu-
lation screening, compared to 12.7% (95% CI 8.6-18.3) in studies 
performed at referral or teaching hospitals. Substantial heterogene-
ity was observed between studies, and the majority of them reported 
outcomes from cohorts of less than 200 patients. Nevertheless, our 
study provides a basis for estimating the number of HBV-infected 
individuals in need of immediate antiviral therapy because of the 
presence of cirrhosis in sub-Saharan Africa.
The type of study setting had a strong impact on the prevalence 
of cirrhosis observed: Studies from tertiary care centres reported 
a prevalence of up to 22%, which arguably reflected the fact that 
patients with more advanced diseases were referred to such cen-
tres for specialized care. The estimate of 4.1% derived from studies 
from primary care and population screening was fairly robust and is 
more likely to represent the prevalence in the general population in 
sub-Saharan Africa. The difference in prevalence between the two 
types of setting is illustrated by the comparison of the estimates of 
the two largest studies: Among 402 individuals identified through 
community-based screening in the Gambia, the prevalence of cir-
rhosis was 2.8%18; in contrast, of 1190 individuals with chronic HBV 
infection referred to a teaching hospital in Ethiopia, 17.3% were di-
agnosed with cirrhosis.13
The studies included varied in terms of the methods used to 
assess liver fibrosis and cirrhosis. Whereas there was substantial 
heterogeneity among studies reporting on cirrhosis, we found no 
evidence that the method of cirrhosis assessment contributed sig-
nificantly to the estimates. This finding was surprising, since the 
sensitivity of APRI to diagnose cirrhosis is considered low, leading 
to many cases of cirrhosis being missed.5 Studies from Europe and 
Ethiopia have shown that between two-thirds and 80% of individu-
als with HBV-related cirrhosis are missed when fibrosis is assessed 
with the APRI score.13,28 However, since we were unable to compare 
transient elastography and APRI scores within the same studies, and 
only few large studies using APRI were available for this review, the 
analyses on the impact of fibrosis assessment method on cirrhosis 
prevalence should be interpreted with caution.
HIV co-infection can significantly alter the course of HBV-related 
liver disease progression. Whereas co-infected patients seem to be 
more likely to develop chronic infection, it is unclear whether and 
to what extent HIV/HBV co-infection influences the development 
of cirrhosis in sub-Saharan Africa, where HBV infection is generally 
acquired years before HIV infection.29 In our meta-analysis, stud-
ies performed in HIV/HBV co-infected patients reported a higher 
prevalence of cirrhosis compared to studies in HBV mono-infected 
patients, but co-infection was not significantly associated with cir-
rhosis in multivariable meta-regression. Comparative studies be-
tween HBV mono-infected and HIV/HBV-coinfected individuals 
within the same settings are needed to better understand the po-
tential impact of HIV infection on HBV-related cirrhosis.
Our study provides robust pooled estimates of the prevalence 
of cirrhosis among HBV-infected individuals in sub-Saharan Africa, 
which will help determine and plan HBV treatment needs. Meta-
regression analyses allowed us to confirm the strong association 
between study setting and cirrhosis prevalence, whereas the role of 
HIV infection seemed less evident. However, the substantial residual 
heterogeneity of the subgroup analysis stratified by study setting in-
dicates that other explanatory factors might not have been captured 
in our study. For instance, we relied on the cut-offs for transient 
elastography defined in each individual study, albeit the thresholds 
used in the studies differed significantly, potentially contributing to 
between-study heterogeneity. This was especially true for studies 
performed among HIV/HBV co-infected individuals, a population 
for which optimal transient elastography cut-offs remain ill-defined. 
Despite a broad literature search without language and date restric-
tions, we found only few large studies, which assessed the pres-
ence of cirrhosis with transient elastography, and the low number 
of studies limited the statistical power to reliably detect differences 
between subgroups. Close to two-thirds of the individuals included 
in our meta-analysis were from cohorts in the Gambia and Ethiopia, 
and many African countries were not represented in our analyses. 
Finally, there was only limited information about the proportion of 
patients with a positive HBeAg in most studies. Differences in the 
prevalence of HBeAg-positivity may have had an impact on the pro-
gression of liver fibrosis, as shown in studies from other regions.30
In summary, we show that a significant proportion of the HBV-
infected population in sub-Saharan Africa has cirrhosis. Our findings 
have important policy implications for resource allocation strategies 
and national HBV treatment programs in order to achieve the WHO 
elimination goals by 2030. According to the WHO, only 150 000 
HBV-infected individuals had been diagnosed by 2015 in sub- 
Saharan Africa, and 18% of them had received antiviral treatment.8 
Based on the results from our meta-analysis, 2.5 Million of the esti-
mated 60 Million people with chronic HBV infection in sub-Saharan 
Africa have cirrhosis and need immediate antiviral therapy and HCC 
screening.8,31 More efforts are needed to identify HBV-infected in-
dividuals in SSA, and to systematically assess the extent of HBV-
associated liver disease. Since widely available tests such as the APRI 
score miss a significant proportion of cases of cirrhosis, there is an 
urgent need for access to more accurate cirrhosis assessment tools 
such as transient elastography in order to identify patients for whom 
HBV therapy and surveillance are crucial.
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